Published by
@ShahidNShah
@ShahidNShah
FoundationOne Liquid CDx is an FDA-approved companion diagnostic
FoundationOne Liquid CDx is a diagnostic tool that utilizes a simple blood draw to analyze over 300 genes recommended by guidelines. It is the only FDA-approved liquid biopsy that analyzes this many genes and it also provides bTMB, MSI-H and tumor fraction values as a professional service. This product is designed to help guide treatment strategies and predict patient benefit across multiple cancer indications.
The features of this product include the analysis of over 300 genes, bTMB and MSI-H, inclusion of guideline-recommended genes and biomarkers to guide therapy selection and identify clinical trial options for patients with solid tumors. It requires only two 8.5mL tubes of blood and it has demonstrated clinical outcomes data with advanced prostate cancer patients identified as BRCA1/2+ by a simple blood draw with FoundationOne Liquid CDx demonstrated a 59% confirmed PSA response rate to Rubraca® (rucaparib) in the TRITON clinical studies.
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Dec 20, 2024 at 12:59pm